Mesoblast Plans New GvHD Trial After Another FDA Rejection
Mesoblast plans to conduct a new trial for evaluating the efficacy of remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (GvHD),…
Mesoblast plans to conduct a new trial for evaluating the efficacy of remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (GvHD),…
NSM acquires three companies to bolster its portfolio of leading specialty insurance productsCONSHOHOCKEN, PA, March 20, 2023 – NSM Insurance Group, the nation’s leading specialty insurance…
Orchard Therapeutics announced the U.S. Food and Drug Administration has approved Lenmeldy™, formerly known as OTL-200, for the treatment of children with pre-symptomatic late…
As cybercriminals target valuable health and personal data, cyberattacks are a growing threat for healthcare organizations and self-insured companies. In a feature article for The…
Pfizer will offer a warranty program for its first FDA-approved gene therapy. The hemophilia B treatment will go for $3.5M, matching the price tag…
Kebilidi represents the 13th gene therapy to score an FDA nod, but it's the first gene therapy to be administered directly in the brain.
Despite mixed results in testing, agency officials determined Elevidys showed enough to warrant a label that includes all patients at least 4 years of…
Conshohocken, PA, October 24, 2023 – Sequoia Reinsurance Services and IOA Re are pleased to announce a collaboration with Everest Reinsurance Company (“Everest”) and/or its affiliates to expand their…
The high cost of healthcare claims is just one of several market challenges facing self-insured employers today. The cost of preventable hospital-acquired conditions adds…
Beyond being a major public health challenge, obesity carries extreme implications for employers and their teams. In fact, a recent report estimates obesity cost…